Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Innovazioni future nella nuova rilevazione della fibrillazione atriale (FIND-AF): studio pilota (FIND-AF)

30 settembre 2026 aggiornato da: Prof Christopher Gale, University of Leeds

Innovazioni future nella nuova rilevazione della fibrillazione atriale (FIND-AF): studio pilota su un punteggio di rischio per la diagnosi precoce della fibrillazione atriale

The purpose of this study is to trial a new intervention - risk-guided AF screening using an EHR-based risk score and remote ECG monitoring process - and to characterise individuals at elevated predicted AF risk.

Panoramica dello studio

Stato

Attivo, non reclutante

Intervento / Trattamento

Descrizione dettagliata

This pilot study will use a post-market device within its intended purpose and involve a change in standard care - that is the offer of ECG monitoring for individuals at risk of AF to understand whether this leads to an increase in detection rates of AF, and follow-through prescription of oral anticoagulation.

Starting with the population that are eligible for oral anticoagulation (men with a CHA2DS2VASC ≥ 2 and women with a CHA2DS2VASC ≥ 3), but without AF, this pilot study will use FIND-AF within its intended purpose to predict the absolute risk of AF diagnosis for individuals within the next 6 months. It will be observed whether systematic AF screening leads to higher detection rates of AF in individuals at higher risk for AF than individuals at lower risk for AF.

This will give pilot data for whether systematic screening for AF in individuals at higher AF risk results in an incrementally higher yield of AF detection compared with screening approaches that have been targeted by age and risk of AF-related stroke. If the pilot shows that detection rates for AF are higher in the group at higher AF risk, then it would be suitable to plan a randomised controlled trial to determine whether systematic AF screening guided by AF risk increases detection rates of AF compared with routine care, and whether this is associated with a lower rate of stroke. The detection rates during systematic AF screening in this pilot study for individuals at higher and lower risk can establish power calculations required for a full-scale study and whether the numeric score at which a clinician would implement the intervention can be optimised.

In addition, this pilot study will establish the technical, logistic and administrative feasibility of a full-scale remote AF screening study including issues of recruitment and protocol adherence. It will also inform as to whether individuals diagnosed with AF by systematic AF screening in the community will receive oral anticoagulation interventions in primary care, and thus whether treatment of screen-detected AF in a full-scale study should be implemented in primary care or in secondary care under cardiology.

Finally this study will offer participants at higher AF risk the opportunity to attend a research clinic to determine whether these individuals have risk factors and comorbidities that could be identified and treated to reduce their subsequent risk of AF and other adverse events. This will establish whether individuals at risk of AF will attend for review, and their burden of modifiable risk factors for AF. This will establish power calculations that would be required for a full-scale study to test the hypothesis that primary prevention of AF is possible through interventions aimed at individuals at risk of AF.

Tipo di studio

Osservativo

Iscrizione (Stimato)

1955

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • West Yorkshire
      • Leeds, West Yorkshire, Regno Unito, LS2 9JT
        • University of Leeds

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

30 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Metodo di campionamento

Campione non probabilistico

Popolazione di studio

Patients aged >30 will be invited to screening in primary care from information present in their electronic health record (EHR) and their FIND-AF score. They will be given Zenicor ECG devices for up to period of 3 week during which they will be asked to record 4 daily ECG recordings.

Those patients who are higher risk for AF based on their FIND-AF score, will be reviewed further for multi-modal phenotyping.

Patient with new AF detected will be managed by their primary care clinicians.

Descrizione

Inclusion Criteria:

  • Age at enrolment ≥30 years
  • Men with CHA2DS2VASC ≥ 2 and women with a CHA2DS2VASC ≥ 3

Exclusion Criteria:

  • Known diagnosis of AF
  • On anticoagulation therapy
  • On the palliative care register
  • Unable to give written informed consent for participation in the study
  • Unable to adhere to the study requirements

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Modelli osservazionali: COHORT
  • Prospettive temporali: PROSPECTIVE

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
To determine whether detection rates of AF during ECG monitoring are higher amongst participants identified as higher risk of AF, compared with those identified as lower risk
Lasso di tempo: 6 months

Rate ratio of AF detection rates during ECG monitoring in participants identified as higher risk by FIND-AF compared with participants identified as lower risk

6 months
To determine whether detection rates of AF during ECG monitoring are higher amongst participants identified as higher risk of AF, compared with those identified as lower risk
Lasso di tempo: 5 years

Rate ratio of AF detection rates during ECG monitoring in participants identified as higher risk by FIND-AF compared with participants identified as lower risk

5 years
To determine whether detection rates of AF during ECG monitoring are higher amongst participants identified as higher risk of AF, compared with those identified as lower risk
Lasso di tempo: 10 years

Rate ratio of AF detection rates during ECG monitoring in participants identified as higher risk by FIND-AF compared with participants identified as lower risk

10 years

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
To determine, of participants who are detected as having AF during ECG monitoring, the proportion who subsequently receive oral anticoagulation prescription
Lasso di tempo: 6 months

Number (%) of participants who receive an oral anticoagulant prescription after diagnoses of AF during ECG monitoring diagnosed

6 months
To determine, of participants who are detected as having AF during ECG monitoring, the proportion who subsequently receive oral anticoagulation prescription
Lasso di tempo: 5 years

Number (%) of participants who receive an oral anticoagulant prescription after diagnoses of AF during ECG monitoring diagnosed

5 years
To determine, of participants who are detected as having AF during ECG monitoring, the proportion who subsequently receive oral anticoagulation prescription
Lasso di tempo: 10 years

Number (%) of participants who receive an oral anticoagulant prescription after diagnoses of AF during ECG monitoring diagnosed

10 years

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
To determine the AF detection rates amongst participants who are identified as higher risk and lower risk, including in the periods outside of ECG monitoring to determine the incremental yield that is achieved by ECG monitoring over routine care
Lasso di tempo: 6 months

Risk of recorded AF diagnosis in EHR between individuals identified at higher and lower risk at six months after enrolment

6 months
To determine how diagnostic yield, C statistic/AUROC, NPV, PPV, sensitivity and specificity, varies at different cut off points of the FIND-AF risk score
Lasso di tempo: 6 months

Diagnostic yield, PPV, NPV, sensitivity and specificity amongst participants who receive ECG monitoring, to understand whether the numeric score at which a clinician implements ECG monitoring can be optimised

6 months
To determine the C statistic/AUROC, NPV, PPV, sensitivity and specificity for alternative approaches to guide systematic AF screening in participants who receive ECG monitoring:
Lasso di tempo: 6 months

Diagnostic yield, C statistic/AUROC, PPV, NPV, sensitivity and specificity in patients who are : CHA2DS2VASC≥3 in men and CHA2DS2VASC≥4 in women, age ≥70 years and age 75 and 76 years

6 months
To determine if yield from ECG monitoring varies across age groups (≥75 years and ≤75 years) and sex (men and women)
Lasso di tempo: 6 months

AF detection rates and risks comparing higher and lower risk participants stratified by subgroup

6 months
To determine recruitment rates, overall study.
Lasso di tempo: Up to 24 months

Number (%) of people who consent to participate compared to number of people who are invited

Up to 24 months
To determine withdrawal rates
Lasso di tempo: Up to 24 months

Number (%) of people who consent to participate but subsequently withdraw consent / decline ECG monitoring

Up to 24 months
To determine if there are differences between those who participate and those that do not participate
Lasso di tempo: Up to 24 months

Characteristics of those who consent to participate and do not consent to participate

Up to 24 months
To determine if there are differences between those who participate and those that withdraw
Lasso di tempo: Up to 24 months

Characteristics of those who participate and those that withdraw

Up to 24 months
To determine the adherence of ECG recordings amongst participants
Lasso di tempo: Up to 24 months

Mean number of recordings compared to the maximum stipulated Number (%) of participants who record less than 50% of stipulated amount of ECG recordings

Up to 24 months
To determine the number of ECG recordings that need to be reviewed for possible AF detection
Lasso di tempo: Up to 24 months

Number (%) of ECG recordings flagged as abnormal by the algorithm within ECG recorder software that require manual review to assess for potential AF diagnosis

Up to 24 months
To determine the burden of other arrhythmias that are diagnosed through ECG monitoring in participants identified as higher risk and lower risk
Lasso di tempo: Up to 24 months

Number (%) of participants who are diagnosed with other arrhythmias ( (atrial tachycardia, supraventricular tachycardia, 2nd degree AV block, high grade AV block or 3rd degree heart block, pause/asystole, ventricular tachycardia, ventricular fibrillation) during ECG monitoring in participants

Up to 24 months
To determine the burden of non-diagnostic rhythm reports from ECG monitoring
Lasso di tempo: Up to 24 months

Number (%) of participants who have an ECG monitoring period with consistent poor quality which precludes a diagnostic result

Up to 24 months
To determine recruitment rates - research clinic appointment
Lasso di tempo: Up to 24 months

Number (%) of people who consent to attend a research clinic appointment compared to number of people who are invited

Up to 24 months
To determine what other conditions and cardiovascular risk factors are identified amongst participants classified as higher risk for AF at research clinic
Lasso di tempo: End of recruitment

Descriptive statistics of demographics, morbidities, medications, and cardiac ultrasound findings

End of recruitment
To observe the clinical outcomes of participants that participate in the study, and whether there is a difference between participants identified as higher and lower risk?
Lasso di tempo: 5 years from completion of recruitment

Number (%) of participants who experience at 5 years:

  • AF
  • Ischaemic stroke
  • Haemorrhagic stroke
  • Systemic embolism
  • Gastrointestinal or intracranial bleeding
  • Death
  • Chronic obstructive pulmonary disease
  • Chronic kidney disease
  • Heart failure
  • Diabetes mellitus
  • Myocardial infarction
  • Peripheral vascular disease
  • Valvular heart disease
5 years from completion of recruitment
To observe the clinical outcomes of participants that participate in the study, and whether there is a difference between participants identified as higher and lower risk?
Lasso di tempo: 10 years from completion of recruitment

Number (%) of participants who experience at 10 years:

  • AF
  • Ischaemic stroke
  • Haemorrhagic stroke
  • Systemic embolism
  • Gastrointestinal or intracranial bleeding
  • Death
  • Chronic obstructive pulmonary disease
  • Chronic kidney disease
  • Heart failure
  • Diabetes mellitus
  • Myocardial infarction
  • Peripheral vascular disease
  • Valvular heart disease
10 years from completion of recruitment

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Investigatore principale: Chris Gale, Yes, University of Leeds

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

1 ottobre 2023

Completamento primario (Effettivo)

16 giugno 2025

Completamento dello studio (Stimato)

28 febbraio 2033

Date di iscrizione allo studio

Primo inviato

18 maggio 2023

Primo inviato che soddisfa i criteri di controllo qualità

31 maggio 2023

Primo Inserito (Effettivo)

12 giugno 2023

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

2 ottobre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

30 settembre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Descrizione del piano IPD

No individual participant data will be shared.

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi